Published in Blood Cancer J on October 04, 2013
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol (2016) 0.81
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol (2010) 2.66
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol (2009) 1.92
Quantification of mRNA in whole blood by assessing recovery of RNA and efficiency of cDNA synthesis. Clin Chem (2006) 1.68
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer (2007) 1.66
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res (2005) 1.62
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol (2008) 1.50
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol (2008) 1.23
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol (2010) 1.15
Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol (2008) 1.04
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood (2011) 1.03
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol (2006) 1.02
Ex vivo simulation of leukocyte function: stimulation of specific subset of leukocytes in whole blood followed by the measurement of function-associated mRNAs. J Immunol Methods (2010) 0.91
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res (2009) 0.91
Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. Int J Hematol (2008) 0.90
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica (2011) 0.87
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst (2008) 0.86
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer (2010) 0.85
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol (2011) 0.84
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma (2008) 0.80
Images in clinical Medicine. Bortezomib-induced skin lesions. N Engl J Med (2005) 0.79
Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol (2001) 13.98
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother (1975) 8.67
Resetting central and peripheral circadian oscillators in transgenic rats. Science (2000) 8.63
Pipemidic acid: its activities against various experimental infections. Antimicrob Agents Chemother (1976) 7.92
Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology (2007) 6.61
Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother (1975) 6.38
Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
A novel integron-like element carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother (1995) 6.00
Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95
Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc Natl Acad Sci U S A (1980) 5.55
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother (1983) 5.45
Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun (1993) 4.32
The Drosophila mushroom body is a quadruple structure of clonal units each of which contains a virtually identical set of neurones and glial cells. Development (1997) 4.14
A mutation in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nematodes. Nature (1998) 4.06
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation (1995) 3.82
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma (1984) 3.74
New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. J Bacteriol (1981) 3.65
Formation and reversion of Streptomycete protoplasts: cultural condition and morphological study. J Gen Microbiol (1974) 3.56
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res (2001) 3.51
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci (2001) 3.50
Molecular structure of a gene, VMA1, encoding the catalytic subunit of H(+)-translocating adenosine triphosphatase from vacuolar membranes of Saccharomyces cerevisiae. J Biol Chem (1990) 3.47
Autophagosome requires specific early Sec proteins for its formation and NSF/SNARE for vacuolar fusion. Mol Biol Cell (2001) 3.41
Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34
Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants. Plant Cell Physiol (1996) 3.30
Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature (2001) 3.24
Effective elimination of drug resistance and sex factors in Escherichia coli by sodium dodecyl sulfate. J Bacteriol (1968) 3.22
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 3.18
Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids. Antimicrob Agents Chemother (1978) 3.12
Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol (1993) 3.08
An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology (1999) 3.00
Pendrin, encoded by the Pendred syndrome gene, resides in the apical region of renal intercalated cells and mediates bicarbonate secretion. Proc Natl Acad Sci U S A (2001) 2.97
Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med (2001) 2.96
AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science (1989) 2.93
Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem (1991) 2.89
Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol (1975) 2.86
Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem (1996) 2.85
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Phylogenetic analysis of the coryneform bacteria by 5S rRNA sequences. J Bacteriol (1987) 2.83
Molecular cloning and sequence determination of cDNAs for alpha subunits of the guanine nucleotide-binding proteins Gs, Gi, and Go from rat brain. Proc Natl Acad Sci U S A (1986) 2.83
Primary structure of elongation factor Tu from Escherichia coli. Proc Natl Acad Sci U S A (1980) 2.72
Xenopus M phase MAP kinase: isolation of its cDNA and activation by MPF. EMBO J (1991) 2.68
Requirement of CD9 on the egg plasma membrane for fertilization. Science (2000) 2.65
Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet (1995) 2.64
Structure and physiological function of calpains. Biochem J (1997) 2.62
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol (1989) 2.61
Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem (1983) 2.58
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother (1983) 2.58
C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Natl Acad Sci U S A (1994) 2.57
Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int (2006) 2.57
Isolation of a second yeast Saccharomyces cerevisiae gene (GPA2) coding for guanine nucleotide-binding regulatory protein: studies on its structure and possible functions. Proc Natl Acad Sci U S A (1988) 2.54
Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell (1996) 2.53
Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein? Nature (1985) 2.52
Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol (2003) 2.52
Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. Proc Natl Acad Sci U S A (1970) 2.48
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (1997) 2.46
A novel phorbol ester receptor/protein kinase, nPKC, distantly related to the protein kinase C family. Cell (1988) 2.44
Leukocytosis-promoting factor of Bordetella pertussis. 3. Its identity with protective antigen. Infect Immun (1974) 2.43
Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun (1995) 2.42
Gene cloning of chitinase A1 from Bacillus circulans WL-12 revealed its evolutionary relationship to Serratia chitinase and to the type III homology units of fibronectin. J Biol Chem (1990) 2.38
Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect Immun (1999) 2.38
Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 2.36
Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J (1994) 2.33
Comparative study on adhesive performance of functional monomers. J Dent Res (2004) 2.32
Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J Exp Med (1991) 2.31
Use of recombinant human bone morphogenetic protein-2 to enhance tendon healing in a bone tunnel. Am J Sports Med (1999) 2.29
Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature (1984) 2.29
A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood (1994) 2.27
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci U S A (1990) 2.26
Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol (1997) 2.25
Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun (1989) 2.23
Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol (1982) 2.22
Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Head Neck (1997) 2.21
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Characterization of pseudotype VSV possessing HCV envelope proteins. Virology (2001) 2.15
Occurrence in Saccharomyces cerevisiae of a gene homologous to the cDNA coding for the alpha subunit of mammalian G proteins. Proc Natl Acad Sci U S A (1987) 2.15
Crossed aphasia elicited by direct cortical stimulation. Neurology (2006) 2.15
Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res (2001) 2.14
Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology (1995) 2.14
Tissue-specific expression of three distinct types of rabbit protein kinase C. Nature (1987) 2.14
Pericardial closure using fascia lata in patients undergoing pneumonectomy with pericardiectomy. Ann Thorac Surg (1998) 2.13
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Surgical anatomy of the hepatic veins and the inferior vena cava. Surg Gynecol Obstet (1981) 2.12
A phorbol ester receptor/protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin. J Biol Chem (1990) 2.12
Cloning of nicotianamine synthase genes, novel genes involved in the biosynthesis of phytosiderophores. Plant Physiol (1999) 2.11
Specific phases of root hair attachment in the Rhizobium trifolii-clover symbiosis. Appl Environ Microbiol (1984) 2.10
Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A (1997) 2.10
A case of Cushing's syndrome due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy. J Urol (1997) 2.08